Clinical trials: Localised Prostate Cancer
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Prostate Adenocarcinoma, Localized Prostate Carcinoma
Two-fraction HDR Monotherapy for Localized Prostate Cancer
This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart.
- Trial name
- NCT05665738
- Testing
- High Dose Rate Monotherapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Opioid Consumption, Postoperative, Multimodal Analgesia
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
This prospective, interventional, open-label, phase 3 randomized study evaluates a multimodal analgesia discharge pathway to reduce automatic opioid prescribing following routine robotic-assisted laparoscopic prostatectomy…
- Conditions
- Opioid Consumption, Postoperative, Multimodal Analgesia, Robotic Assisted Laparoscopic Surgery, Robotic Assisted Laparoscopic Radical Prostatectomy
- Trial name
- ROPES (NCT07427043)
- Testing
- multimodal analgesia pathway with up-front small opioid prescription, multimodal analgesia pathway without up-front small opioid prescription, pre-implementation baseline including opioid
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Brigham and Women's Hospital
Prostate Cancer, Cancer of Prostate
Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
This is a pilot study of the tolerability and safety of neoadjuvant dapagliflozin for patients with unfavorable intermediate, high-risk, or very high-risk prostatic adenocarcinoma prior to radical prostatectomy.
- Trial name
- NCT04887935
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer
Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)
Objectives: Primary: To evaluate the association of the probability of increase in phosphorylation of platelet-derived growth factor receptor (PDGFR) of > 0.5 in peripheral blood leucocytes following pre-operative docetaxel…
- Trial name
- NCT00811031
- Testing
- Taxotere, Prednisone
- Sponsor
- M.D. Anderson Cancer Center
PROSTATE CANCER
Two-fraction Versus Five-fraction Stereotactic Radiotherapy for Localized Prostate Cancer
The goal of this clinical trial is to compare two dose schedules of stereotactic radiation therapy in patients with localized prostate cancer.
- Trial name
- SABR-Dual (NCT06027892)
- Testing
- Two-fraction stereotactic radiotherapy, Five-fraction stereotactic radiotherapy
- Where
- Israel
- Volunteers
- 562 people
- Sponsor
- Rabin Medical Center
Prostate Adenocarcinoma
Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer
This study is a prospective, open label, single arm phase II trial. A total of 22 patients will be treated with atezolizumab, PROSTVAC, and pre-operative MVA-BN-Brachyury to confirm the efficacy of prostatic combination…
- Trial name
- AtezoVax (NCT04020094)
- Testing
- MVA-BN-Brachyury
- Where
- United States
- Sponsor
- University of Utah
Prostate Cancer, Prostate Adenocarcinoma
A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer
Men with localized, intermediate risk prostate cancer will be randomized to undergo either radical prostatectomy or the TULSA procedure, with a follow-up of 10 years in this multi-centered randomized control trial.
- Trial name
- CAPTAIN (NCT05027477)
- Testing
- Radical Prostatectomy, TULSA Procedure
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 201 people
- Sponsor
- Profound Medical Inc.
Prostate Cancer
Stereotactic MRI-Guided Radiation for Localized Prostate Cancer
This single arm, prospective study will determine the prostate-specific quality of life (QOL) of patients undergoing undergoing a 2 fraction MRI-guided stereotactic ablative body radiation (SABR) protocol.
- Trial name
- 2SMART (NCT03588819)
- Testing
- SABR
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer
Intensity-modulated Radiation Therapy From 70Gy to 80Gy in Localized Prostate Cancer
The objective is to report outcomes,including grade ≥2 overall late rectal and urinary toxicity and biochemical control rates in patients treated with IMRT (70 gy, 74 Gy and 80 Gy)
- Trial name
- NCT02974231
- Testing
- Intensity-modulated radiation therapy
- Volunteers
- 240 people
- Sponsor
- Institut de Cancérologie de Lorraine
Prostate Cancer
Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer
The aim of this study is to determine the maximum tolerated dose of hypo-fractionated radiation therapy and the toxicity of the treatment program.
- Trial name
- NCT01677845
- Testing
- Radiation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- NYU Langone Health
Prostatic Neoplasms
Feasibility Study of Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer: Cyberknife vs. VMAT
Recent studies support the use of Stereotactic Body Radiation Therapy (SBRT) for the treatment of localized prostate cancer (PrCa).
- Trial name
- NCT02344667
- Testing
- Stereotactic Body Radiotherapy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Juravinski Cancer Center
Intermediate Risk Prostate Cancer (Diagnosis), Prostate Cancer
Dose-dEscalated MR-Guided Radiotherapy for Localized Prostate Cancer
DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT).
- Trial name
- DESTINATION 2 (NCT07674225)
- Testing
- Prostate radical radiotherapy
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Sunnybrook Health Sciences Centre
Cancer of Prostate
Dynamic Focusing Evaluation for Prostate Cancer Treatment
Define the best acoustic parameters for the dynamic focusing HIFU transducer in the treatment of localized Prostate Cancer.
- Trial name
- FOC/DYN (NCT03632980)
- Testing
- "Ablatherm Foc/Dyn" or "Focal One" HIFU treatment
- Where
- France
- Volunteers
- 180 people
- Sponsor
- EDAP TMS S.A.
Prostate Cancer
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Bicalutamide and goserelin may fight prostate cancer by reducing the production of testosterone.
- Trial name
- NCT00021450
- Testing
- bicalutamide, goserelin acetate, adjuvant therapy
- Where
- 20 sites in Belgium, Cyprus and 9 more
- Volunteers
- 819 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer
Purpose: The purpose of this clinical trial is to look at the chemotherapy combination of docetaxel and capecitabine in the treatment of newly diagnosed or locally advanced prostate cancer, and to determine if this treatment is…
- Trial name
- NCT00151047
- Testing
- Capecitabine, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer
Health-Related Quality of Life in Gay Men With Localized Prostate Cancer
RATIONALE: Gathering information about prostate cancer, treatment, and quality of life from gay men with prostate cancer may help doctors plan the best treatment.
- Trial name
- NCT00828633
- Where
- 3 sites in United States, Canada
- Volunteers
- 92 people
- Sponsor
- Baylor College of Medicine
Prostate Cancer
Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer
The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.
- Trial name
- VAPOR 2 (NCT05683691)
- Testing
- Vanquish System
- Where
- 25 sites in United States
- Volunteers
- 400 people
- Sponsor
- Francis Medical Inc.
Prostate Cancer
Radiation Therapy Followed by Surgery in High-Risk, Localized Carcinoma of the Prostate
The purpose of the study is to assess the safety of four different doses of radiation therapy followed by to surgery to remove prostate tumor.
- Trial name
- NCT00691977
- Testing
- Radiation Therapy followed by prostatectomy
- Where
- United States
- Sponsor
- Virginia Commonwealth University
Prostate Cancer
Study of POMELLA™ Extract to Treat Prostate Cancer
This is a randomized, two-arm, placebo controlled trial to evaluate benefit of treatment using POMELLA™ extract on mechanisms known to drive prostate cancer.
- Trial name
- NCT01100866
- Testing
- POMELLA™ (pomegranate extract)
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Vancouver Coastal Health